Raugh, Ian M.
Strauss, Gregory P.
Funding for this research was provided by:
National Institute of Mental Health (R21-MH112925)
Article History
Received: 2 March 2021
Accepted: 19 October 2021
First Online: 30 October 2021
Declarations
:
: G.P.S. is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from Medavante-ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. GPS has received honoraria and travel support from Medavante-ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past 2 years, GPS has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Acadia, and Lundbeck pharmaceutical companies. All other authors have no relevant disclosures to report.
: The study was approved by the University of Georgia Institutional Review Board. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: All participants provided written informed consent to participate.
: All authors have consented for the manuscript to be submitted for publication.